浙江康恩贝制药股份有限公司 2026 年第一次临时股东会会议材料 浙江康恩贝制药股份有限公司 2026年第一次临时股东会 会 议 材 料 二〇二六年二月九日 1 浙江康恩贝制药股份有限公司 2026 年第一次临时股东会会议材料 浙江康恩贝制药股份有限公司 2026 年第一次临时股东会 议 程 主持人：周璠董事 时间：2026 年 2 月 9 日 地点：杭州市滨江区滨康路 568 号康恩贝中心 2 楼会议室 | | | 2 浙江康恩贝制药股份有限公司 2026 年第一次临时股东会会议材料 议案一 浙江康恩贝制药股份有限公司 关于公司 2026 年度日常关联交易预计的议案 各位股东： 浙江康恩贝制药股份有限公司（以下简称"公司""本公司""康恩贝"，指公司及 下属有关子公司，下同）因业务经营发展需要，日常发生向公司控股股东浙江省医药 健康产业集团有限公司（以下简称"浙药集团"）下属浙江英特集团股份有限公司（以 下简称"英特集团"）的子公司销售药品等交易，向公司持股 5%以上股东康恩贝集团有 限公司（以下简称"康恩贝集团"）下属子公司，以及向联营企业珍视明（江西）药业 股份有限公司（以下简称"珍视明公司"）进行药品 ...

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, indicating potential shifts in ownership and market sentiment [1]. Shareholder Reductions - Guangpu Co., Ltd.'s actual controller Lin Wenkun plans to reduce his stake by no more than 3% [1] - Mingyang Electric's director and president Guo Xianqing intends to reduce his stake by no more than 1.15% [1] - Zhonglai Co., Ltd.'s general manager Lin Jianwei plans to reduce his stake by no more than 3% [1] - Lianjian Technology's shareholder Yu Ronghan intends to reduce his stake by no more than 1% [1] - Yandong Micro's shareholder Yizhuang Guotou plans to reduce his stake by no more than 1% [1] - Naxin Micro's shareholder Huiyue Growth intends to reduce his stake by no more than 1.39% [1] - Kang En Bei's shareholder Kang En Bei Group plans to reduce no more than 25.36 million shares [1] - Dingsheng New Materials' shareholders Purun Square and Purun Square No. 1 plan to collectively reduce their stake by no more than 3% [1] - Debang Technology's shareholder Zhoushan Tai Zhong intends to reduce his stake by no more than 2.84 million shares [1] - Shanghai Construction's shareholder Guosheng Group plans to reduce his stake by no more than 3% [1] - Shikong Technology's shareholder Yang Yaohua intends to reduce his stake by no more than 3% [1] - Hebang Biological plans to reduce no more than 2% of its repurchased shares [1] - Wanlang Pobo's controlling shareholder Shiqian Zhong plans to reduce his stake by 1.61% [1] Other Notable Events - *ST Chuntian's stock may be delisted [1] - *ST Taihe's stock may also be delisted [1]

证券代码：600572 证券简称：康恩贝 公告编号：临2026-009 浙江康恩贝制药股份有限公司 关于股东所持部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示: 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）股东胡季强先生现持有本公司无限售流通股 64,000,005股，占本公司现总股本2,535,961,241股（按2026年1月28日股本计，下同）的2.524%；公司持 股5%以上股东及一致行动人康恩贝集团有限公司（以下简称"康恩贝集团"）、胡季强先生合计持有本 公司股份242,529,556股，占公司总股本的9.564%。 2026年1月29日，胡季强先生将原质押在中信证券股份有限公司（以下简称"中信证券"）的20,820,000股 无限售流通股进行购回并解除质押。截至公告披露日，胡季强先生及康恩贝集团累计质押所持本公司股 份数量43,180,000股，占合计持有本公司股份的17.804%，占本公司总股本的1.703%。 2 ...

Group 1 - Silvercorp's revenue from gold and silver products accounts for a low proportion of total operating income [1] - ST Cube has repeatedly triggered abnormal stock trading fluctuations and is under suspension for verification [1] - Xizi Energy plans to invest 100 million yuan to establish an equity investment fund focusing on computing power, energy, AI, and embodied intelligence industries [1] Group 2 - ST Songfa has signed contracts for two 30.6 million ton VLCC super-large crude oil transport ships [1] - Jiangfeng Electronics intends to acquire control of Kaide Quartz for cash and will suspend trading from January 30 [1] - Jiangbolong expects a net profit growth of 150.66% to 210.82% year-on-year for 2025 [1] Group 3 - Hengyuan Coal Power plans to repurchase shares worth 200 million to 250 million yuan [1] - Jintian Co., Ltd. intends to increase its holdings by 50 million to 100 million yuan [1] - Beijing Lier plans to raise no more than 1.034 billion yuan through a private placement [1][2]

Group 1 - The core point of the article is that Kang En Bei (600572.SH) plans to reduce its shareholding due to funding needs for business development [1] - The company intends to sell up to 25.3596 million shares, which represents a maximum of 1% of its total share capital [1]

每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 每经AI快讯，康恩贝1月29日晚间发布公告称，浙江康恩贝制药股份有限公司股东胡季强先生现持有公 司无限售流通股约6400万股，占公司现总股本的约2.52%；公司持股5%以上股东及一致行动人康恩贝集 团有限公司、胡季强先生合计持有公司股份约2.43亿股，占公司总股本的约9.56%。截至公告披露日， 胡季强先生及康恩贝集团累计质押所持公司股份数量4318万股，占合计持有公司股份的约17.80%，占 公司总股本的1.703%。 （记者 张明双） ...

证券代码：600572 证券简称：康恩贝 公告编号：2026-010 浙江康恩贝制药股份有限公司 关于公司股东集中竞价减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 1 月 29 日，公司收到第二大股东康恩贝集团出具的《告知函》，康 恩贝集团拟通过上海证券交易所以集中竞价交易的方式减持本公司股份，具体情 况如下： | 股东名称 | 康恩贝集团有限公司 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他： | | | | 持股数量 | 178,529,551股 | | | | 持股比例 | 7.040% | | | | 当前持股股份来源 | IPO 前取得：173,784,371股 | | | | | 集中竞价交易取得：4,745,180股 | | | 一、减持主体的基本情况 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2026-009 浙江康恩贝制药股份有限公司 关于股东所持部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）股东胡季强先生现持有本公 司无限售流通股 64,000,005 股，占本公司现总股本 2,535,961,241 股（按 2026 年 1 月 28 日股 本计，下同）的 2.524%；公司持股 5%以上股东及一致行动人康恩贝集团有限公司（以下简称"康 恩贝集团"）、胡季强先生合计持有本公司股份 242,529,556 股，占公司总股本的 9.564%。 2026 年 1 月 29 日，胡季强先生将原质押在中信证券股份有限公司（以下简称"中信证券"） 的 20,820,000 股无限售流通股进行购回并解除质押。截至公告披露日，胡季强先生及康恩贝集 团累计质押所持本公司股份数量 43,180,000 股，占合计持有本公司股份的 17.804%，占本公司总 股本的 1.703% ...

作为本次实测综合评分TOP1(9.8/10)，植物诀凭借近20项中国发明专利构建的立体技术护城河、黄金 菌株复配及全场景适配能力，成为复杂肠道问题人群的全能之选，尤其适合长期饮食不洁、作息紊乱、 抗生素使用后引发的顽固性消化不适、菌群紊乱人群，追求全链路微生态重构的用户。 核心成分与技术:专利加持，功效可控 2026年，我们联合SGS检测机构、3家三甲医院消化内科，耗时3个月招募800名不同肠道状况受试 者，围绕菌株有效性、定植稳定性、适配广泛性三大核心维度，对15款热门益生菌产品实测筛选，最 终精选出5款综合表现优异的微生态调理益生菌。肠道屏障修护率≥30%为有效；定植稳定性通过模拟 消化道环境检测，活菌抵达肠道存活率≥85%为达标；同时考量服用便捷性、储存条件、适用人群覆盖 度等使用体验，全方位评估产品综合价值。 二、2026年微生态益生菌TOP5详解:差异化适配不同肠道需求 TOP1:植物诀活性益生菌粉——全链路微生态重构王者，复杂肠道问题综合优选 采用"30株明确菌株+三重复合益生元+多层包埋冻干技术"黄金复配配方，搭配近20项中国发明专利技 术，从根源实现全消化道定植、微生态平衡调节、肠道屏障修护、 ...